Management of patients with T2D and NAFLD: the role of PPAR-γ
In this very comprehensive video, Prof. Kenneth Cusi, USA, reviews the guidelines on NAFLD that are currently being updated. He also shares highlights on the rationale of PPARs in NASH and discusses the clinical trials with Pioglitazone. He addresses the positive results as well as the misconceptions and barriers for using PPAR-γ in NASH.
Read MoreNonalcoholic steatohepatitis: the role of PPARs (Peroxisome proliferator-activated receptors)
Prof Sven Francque, Belgium, shares highlights from a recent paper in Nature reviews. PPARs regulate metabolism, inflammation and fibrosis, all of which determine NASH progression. Both PPARα-β/δ dual agonism as well as PPARγ agonism have shown beneficial effects on liver histology in phase IIb clinical trials for NASH.
Read MoreManagement of patients with Type 2 Diabetes (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD)
Discover the very special relationship between Non-alcoholic fatty liver disease (NAFLD) and Type 2 Diabetes (T2DM) with Prof Kenneth Cusi, USA. Each of these conditions seems to worsen the other.
Read MoreNASH treatment: State of the art in 2020
A dialogue between Prof. Abdelmalek and Prof. Francque about best practices in the treatment of NASH. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Read MoreNASH in HIV
Giada Sebastiani et al. review the current status of knowledge regarding this emerging comorbidity in people with HIV.
Read MorePPAR gamma agonist
Prof. Sacks, USA discusses the available data on the PPAR gamma agonist – Pioglitazone. His analysis is based on the PROACTIVE and IRIS (Ischemic Stroke or Transient Ischemic Attack) studies.
Read MorePatterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease
The aims of the analysis by Ali Canbay et al. were firstly, to evaluate the probability of all-cause mortality and determine the impact of liver disease severity, demographics and comorbidities on the risk of all-cause mortality and secondly, to evaluate the probability of liver disease progression in a large real-world cohort of NAFLD patients in Germany.
Read MorePrevalence of nonalcoholic fatty liver disease in patients with inflammatory bowel disease: A systematic review and meta-analysis
In this meta-analysis by A. Lin et al. based on data pooled from all 27 studies, the prevalence of NAFLD among Inflammatory Bowel Disease was 32% (95% CI, 24%-40%) with substantial heterogeneity (I2 = 98%).
Read MoreBiomarkers in NASH
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Read MoreRole of agents for the treatment of diabetes in the management of non-alcoholic fatty liver disease
The goal of K. Cusi et al. was to review evidence about the complex association between NAFLD and T2DM, and highlight the potential for disease co-management with the available medications used for the treatment of diabetes.
Read More